Stroke update 2011
Transcript of Stroke update 2011
![Page 1: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/1.jpg)
Stroke: An update
Asst. Prof. Sombat Muengtaweepongsa, M.D.
Division of Neurology
Faculty of Medicine
Thammasat University
![Page 2: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/2.jpg)
Holistic Stroke Approach
Primary Stroke
Prevention
Acute Stroke Management
Secondary Stroke
Prevention
Rehabilitation
![Page 3: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/3.jpg)
Primary Stroke Prevention
UPDATE
![Page 4: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/4.jpg)
Homocysteine, Folic Acid, and B Vitamins
• Homocysteine: a risk factor for stroke
• VITAmins TO Prevent Stroke (VITATOPS)
aimed to assess whether daily
administration of folic acid, vitamin B6, and
vitamin B12 in patients with recent stroke
or transient ischemic attack lowers
homocysteine and reduces major vascular
events.
![Page 5: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/5.jpg)
VITATOPS: results
![Page 6: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/6.jpg)
VITATOPS: conclusions
• B vitamins have no or at most a marginal
positive effect on reducing vascular
events.
![Page 7: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/7.jpg)
Blood Pressure
• not only blood pressure levels, but also
blood pressure variability account for
stroke risk
• the ideal antihypertensive agent should
lower both blood pressure levels and
variation in blood pressure to reduce
stroke risk (currently do not have such
agents)
![Page 8: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/8.jpg)
Acute Stroke Management
UPDATE
![Page 9: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/9.jpg)
Transient Ischemic Attack
![Page 10: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/10.jpg)
Definition
• time-based definitions of TIA were first advanced in the 1950s and 1960s
• In 1964, Marshall proposed 24 hours as the maximal duration of symptoms
• In the 1975 revision of the NIH classification document, a 24-hour limit for TIAs was adopted.
![Page 11: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/11.jpg)
TISSUE BASED DEFINITION OF TIA
• Proposals have been made for a "tissue-based" definition of TIA that relies on the absence of end-organ injury as assessed by imaging or other techniques.
• A brief episode of neurologic dysfunction caused by focal brain or retinal ischemia, with clinical symptoms typically lasting less than one hour, and without evidence of acute infarction
![Page 12: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/12.jpg)
Copyright ©2004 American Heart Association
Purroy, F. et al. Stroke 2004;35:2313-2319
Graded risk of futures vascular events and the combination of TIA duration and DWI findings
![Page 13: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/13.jpg)
Prognosis of TIA
![Page 14: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/14.jpg)
Copyright ©2004 BMJ Publishing Group Ltd.
Coull, A J et al. BMJ 2004;328:326
Cumulative risk of stroke after a transient ischemic attack (TIA) or minor stroke
![Page 15: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/15.jpg)
ABCD2 score
• Age 60 years = 1
• Blood pressure:
– systolic 140 mm Hg and/or diastolic 90 mm Hg = 1
• Clinical features:
– unilateral weakness = 2
– speech disturbance without weakness = 1
– other = 0
• Duration of symptoms in min
– >60 = 2
– 10–59 = 1,
– <10 = 0
• Diabetes = 1
![Page 16: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/16.jpg)
![Page 17: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/17.jpg)
EXPRESS study
Lancet. 2007 Oct 20;370(9596):1432-42.
![Page 18: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/18.jpg)
• TIA patients should undergo neuroimaging
evaluation within 24 hours of symptom
onset, preferably with magnetic resonance imaging, including diffusion sequences
![Page 19: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/19.jpg)
AHA Guidelines: TIA (Diagnostic)
• noninvasive imaging of the cervical vessels
should be performed and noninvasive imaging
of intracranial vessels is reasonable
• Electrocardiography should occur as soon as
possible after TIA and prolonged cardiac
monitoring and echocardiography are
reasonable in patients in whom the vascular etiology is not yet identified
![Page 20: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/20.jpg)
AHA Guidelines: TIA (Treatment)
• It is reasonable to hospitalize patients
with TIA if they present within 72 hours and have an ABCD2 score ≥ 3.
June 2009
![Page 21: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/21.jpg)
Standard treatment for AIS
1. Intravenous rt-PA within 3 hrs window
(NNT < 10)
2. Stroke unit (NNT 20-30)
3. ASA within 48 hrs (NNT 140)
4. Early decompressive surgery for malignant MCA infarction (NNT 2)
![Page 22: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/22.jpg)
Copyright ©2003 American Heart Association
Graham, G. D. Stroke 2003;34:2847-2850
Symptomatic ICH rates ordered by decreasing sample size
![Page 23: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/23.jpg)
![Page 24: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/24.jpg)
![Page 25: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/25.jpg)
Exclusion Criteria (1)
• Time of symptom onset unknown
• Symptoms improve rapidly/symptoms only
minor before infusion started
• Evidence of ICH by CT
• Severe stroke as assessed clinically (e.g.
NIHSS25) and/or imaging
• Seizure at the onset of stroke
• Symptoms suggestive of subarachnoid
haemorrhage, even if normal CT scanCT, computed tomography; ICH, intracranial haemorrhage;
NIHSS, National Institutes of Health Stroke Scale
![Page 26: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/26.jpg)
• Combination of previous stroke and diabetes
mellitus
• Platelet count of less than 100,000 per cubic
millimeter
• Oral anticoagulant treatment
Exclusion Criteria (2)
![Page 27: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/27.jpg)
*Lees et al. N Engl J Med 2006;354:588-600
*stratified on Cochran–Mantel–Haenszel test,
adjusted for baseline NIHSS scores and time-to-treatment onset
0% 20% 40% 60% 80% 100%Patients
p=0.024
Alteplase
(n=418)
mRS score*
Placebo
(n=403)
1 2 30 4 5 6
27.5
23.321.8 16.4
9.314.124.9
13.7
9.3
8.2
6.78.1
11.4 5.2
Distribution (shift) analysis* day 90
![Page 28: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/28.jpg)
![Page 29: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/29.jpg)
Thrombolytic Therapy (i.v. rtPA)
Guidelines Ischaemic Stroke 2008
![Page 30: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/30.jpg)
Intravenous Thrombolysis
• rtPA should be administered to eligible patients who can be treated the time period of 3 to 4.5 hours after stroke (Class I Recommendation, Level of Evidence B).
August 2009
![Page 31: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/31.jpg)
Treatment rate
100 patients received i.v. rt-PA
59 patients got transferred from outside hospitals in
acute stroke network (59%)
21% of admissions with acute ischemic stroke
0%5%
10%15%20%25%
Thrombolytic rate
Thrombolytic rate
1 Suwanwela Clin Neurol Neurosurg, 2006
2 Grotta Arch Neurol, 2001
![Page 32: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/32.jpg)
Onset To Treatment and Door To Needle
Mean OTT 144 minutes (40 – 270)
Chulalongorn 137 (45 - 180) 1
Houston 137 (30 – 180) 2
Mean Door to needle 54 minutes (15 – 90)
Chulalongorn 72 (20 - 150) 1
Houston 70 (10 – 129) 2
1 Suwanwela Clin Neurol Neurosurg, 2006
2 Grotta Arch Neurol, 2001
![Page 33: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/33.jpg)
Hemorrhage
13 patients have intracerebral hemorrhage (13%),
Chulalongorn 11.8% 1, ECASS III 27% 3
11 asymptomatic or 11%
2 symptomatic (NIHSS worse > 4) with 1 fatal or 2%
(according to ECASS III definition)
NINDS 6.4% 2
Chulalongorn 5.9% 1
ECASS III 2.4% 3
1 Suwanwela Clin Neurol Neurosurg, 2006
2 NINDS N Engl J Med, 1995
3 ECASS III N Engl J Med, 2008
![Page 34: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/34.jpg)
Functional outcomes at 3 months
42%
39%
26%
21%
18%
23%
14%
17%
0% 20% 40% 60% 80% 100% 120%
Thammasat
NINDS
mRS 0-1
mRS 2-3
mRS 4-5
mRS 6
![Page 35: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/35.jpg)
Cerebrolysin
• a compound consisting of free amino acids
and biologically active small peptides that
are products of the enzymatic breakdown
of lipid free brain products
• Experimental models have demonstrated
neuroprotection although the mechanism
of action is unclear
![Page 36: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/36.jpg)
Cerebrolysin for acute ischaemic stroke
The Cochrane Review
• Review content: 7 January 2010.
• one trial involving 146 participants
– no difference in death or adverse events
• not enough evidence to evaluate the effect
of cerebrolysin on survival and
dependency in people with acute
ischaemic stroke
![Page 37: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/37.jpg)
The Safety and Efficacy of Cerebrolysin in Patients
With Acute Ischemic Stroke (CASTA)
• 10-day course of therapy with daily
intravenous administration of 30mL
Cerebrolysin
• Primary Outcome Measures:
– mRS, BI, NIHSS at 90 days
• Study location
– China, Hong Kong, Korea
• Being announced in WSC 2010
![Page 38: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/38.jpg)
![Page 39: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/39.jpg)
![Page 40: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/40.jpg)
Secondary Stroke Prevention
UPDATE
![Page 41: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/41.jpg)
What treatments are available for each etiology?
• For most mechanisms of
cerebral infarction or TIA,
antiplatelet agents are
indicated.
– diagnostic evaluation is aimed
at evaluating potential
mechanisms that would require
something other than an
antiplatelet agent, such as
surgery, endovascular
intervention, anticoagulants,
antibiotics, or
immunosuppressants.
• class I treatment evidence
– symptomatic carotid artery
stenosis greater than 70% with
carotid endarterectomy (CEA)
– anticoagulation for atrial
fibrillation
– anticoagulants for a few
additional cardioembolic
sources
• For most other etiologies,
antiplatelet agents are
recommended
![Page 42: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/42.jpg)
![Page 43: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/43.jpg)
![Page 44: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/44.jpg)
![Page 45: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/45.jpg)
ASA/AHA Guidelines for prevention of stroke
in patients with ischaemic stroke or TIA (2008)
RecommendationClass/Level of
Evidence*
For patients with noncardioembolic stroke or TIA, antiplatelet agents rather than
oral anticoagulation are recommended to reduce the risk of recurrent stroke and
other cardiovascular events.Class I, Level A
Aspirin (50 to 325 mg/d) monotherapy, the combination of aspirin and extended-
release dipyridamole, and clopidogrel monotherapy are all acceptable options for
initial therapy.*
Class I, Level A
The combination of aspirin and extended-release dipyridamole is recommended
over aspirin alone.Class I, Level B
Clopidogrel may be considered over aspirin alone on the basis of direct-comparison
trials. Class IIb, Level B
Addition of aspirin to clopidogrel increases the risk of haemorrhage and is not
routinely recommended for ischaemic stroke or TIA patients unless they have a
specific indication for this therapy (ie, coronary stent or acute coronary syndrome).Class III
For patients allergic to aspirin, clopidogrel is reasonable. Class IIa, Level B
For patients who have an ischaemic cerebrovascular event while taking aspirin,
there is no evidence that increasing the dose of aspirin provides additional benefit.
Although alternative antiplatelet agents are often considered for non-
cardioembolic patients, no single agent or combination has been well studied in
patients who have an event while receiving aspirin.
Adams et al. Stroke 2008; 39: 1647-1652.
![Page 46: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/46.jpg)
Dual antiplatelet therapy
• intracranial symptomatic atherosclerotic
stenosis, a short-term combination therapy
with clopidogrel and aspirin was more
effective than aspirin alone in reducing
microembolic signals
• a short-term combination therapy with
cilostazol and aspirin may reduce
progression of intracranial stenosis
![Page 47: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/47.jpg)
Anticoagulation
• Dabigatran: direct thrombin inhibitor
– equal or superior than warfarin to prevent
emboli but with lower or equal rates of major
hemorrhages
• Rivaroxaban: a factor Xa inhibitor
– noninferior to warfarin for the prevention of
stroke and noncentral nervous system
embolism
![Page 48: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/48.jpg)
Rehabilitation
UPDATE
![Page 49: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/49.jpg)
After 36 weeks, robot-assisted and intensive therapy
had significantly improved motor function as compared
with standard of care.
Potential long-term benefits of intensive rehabilitation in
patients with moderate-to-severe impairment, even years after
a stroke
![Page 50: Stroke update 2011](https://reader033.fdocuments.us/reader033/viewer/2022052505/556b858fd8b42a6c7c8b4e40/html5/thumbnails/50.jpg)
Thank you for your attention